Cosmo Pharmaceuticals N.V. (0RGI.L)
| Previous close | 66.33 |
| Open | 67.40 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 67.40 - 67.50 |
| 52-week range | 67.40 - 67.50 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 9.944M |
| Beta (5Y monthly) | 1.07 |
| PE ratio (TTM) | 0.52 |
| EPS (TTM) | 1.30 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Private companies account for 46% of Cosmo Pharmaceuticals N.V.'s (VTX:COPN) ownership, while individual investors account for 36%
If you want to know who really controls Cosmo Pharmaceuticals N.V. ( VTX:COPN ), then you'll have to look at the makeup...
- EQS Group
Cosmo and Hyphens Announce Signing of License and Supply Agreements for Winlevi® in Southeast Asia
Cosmo Pharmaceuticals N.V. / Key word(s): Agreement21-Dec-2022 / 06:00 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRDublin, Ireland & Singapore – 21 December 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and Hyphens Pharma International Limited (SGX: 1J5) (“Hyphens”) today announced the signing of License and Supply Agreements for Winlevi® (clasco
- EQS Group
Cosmo announces successful Phase III clinical trial of Lumeblue™ in China
Cosmo Pharmaceuticals N.V. / Key word(s): Study resultsCosmo announces successful Phase III clinical trial of Lumeblue™ in China 14.12.2022 / 06:00 GMT/BST Dublin, Ireland – 14 December 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the successful phase III clinical trial of Lumeblue™ in China, sponsored by its partner China Medical System Holdings Limited (CMS) (867.HK). In the trial, Lumeblue™ was compared to placebo in white light colonoscopy with the purpo
